Teva, Samsung Bioepis announce EPYSQLI availability in the U.S.

Teva Pharmaceuticals (TEVA) and Samsung Bioepis (SSNLF) announced the availability of EPYSQLI in the U.S. EPYSQLI is a biosimilar to Soliris for the treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. EPYSQLI will be offered at a 30% discount of the Wholesale Acquisition Cost of the reference product, Soliris, offering one of the greatest cost-saving biosimilars to Soliris in the U.S. In January 2025, Teva and Samsung Bioepis entered into a strategic partnership for the commercialization of EPYSQLI in the U.S. market. Under the terms of the agreement, Samsung Bioepis handles development, manufacturing and supply, while Teva is responsible for the commercialization of the product in the U.S., leveraging its experience and extensive sales and marketing infrastructure.